Skip to main content

Press Releases

more »
Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the results of its
Toggle Summary Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
WESTLAKE VILLAGE, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul , M.D., Ph.D., Chief Medical Officer, and Silvio Traversa , B.Sc., Ph.D., Chief Scientific Officer, are
Toggle Summary Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120  -- Following Positive End-of-Phase 2 meeting with FDA , Sienna continues toward enrolling first patient in Phase 3 program in second half of 2019 WESTLAKE VILLAGE, Calif.
Toggle Summary Sienna Biopharmaceuticals to Present at BAML Health Care Conference
WESTLAKE VILLAGE, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care
Toggle Summary Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif. , May 08, 2019 (GLOBE NEWSWIRE) --   Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019.

SEC Filings

more »

Events

more »
Date Title
Summary Toggle May 15, 2019 at 3:55 PM PDT

BAML Health Care Conference

Location

Encore, Las Vegas
Summary Toggle Mar 11, 2019 at 11:20 AM EDT

Cowen Health Care Conference

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Corporate Presentation

Click here to view our Corporate Presentation.

Stock Information

more »
Volume
Today's Open
Previous Close

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

more »
Firm Analyst
J.P. Morgan
 Chris Schott
Cowen
 Ken Cacciatore
BMO Capital Markets
 Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Corporate Governance

Click here to view our Corporate Governance information.

Transfer Agent

more »

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com